Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Location Directory

Clinical trials in Cleveland, Ohio

This page shows live ClinicalTrials.gov search results for Cleveland, Ohio, with direct links to official study records plus on-page filtering and sorting for broad location searches.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:06 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
11338
Shown on this page
12
Current sort
Recently updated
Location scope
Cleveland, OH
Filters apply within this location only.

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

Filter and sort this location

These controls apply only within Cleveland, Ohio. Default order is Recently updated. Use recruitment status if you want to focus on actively recruiting studies in this location.

Reset location filters
Clear filters
Showing 457–468 of 11,338 matching trials in Cleveland, OH.
Live ClinicalTrials.gov results.
Local directory summary panels are hidden while filters are applied so the page stays focused on the filtered live results.

Institutions in Cleveland

Campus pages list official records that name the campus as a study site. Listed in directory order, not ranked.

Live official records

Open in full search
Active, not recruiting Phase 2 Interventional

A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

NCT05250973
View directory record Official record
Conditions
Amyloidosis
Interventions
Daratumumab, Cyclophosphamide, Bortezomib, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
151 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
16
States / cities
Duarte, California • New Haven, Connecticut • Tampa, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Phase 3 Interventional

Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL

NCT07321652
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Interventions
Zanubrutinib, Sonrotoclax, Computed Tomography, Bone Marrow Aspiration, Biospecimen Collection, Survey Administration
Drug · Procedure · Other
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
65 Years and older
Enrollment
466 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2038
U.S. locations
261
States / cities
Birmingham, Alabama • Anaheim, California • Baldwin Park, California + 213 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Active, not recruiting Phase 3 Interventional

Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer

NCT06619236
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer
Interventions
Rina-S, Paclitaxel, Topotecan, Pegylated liposomal doxorubicin (PLD), Gemcitabine
Drug
Lead sponsor
Genmab
Industry
Eligibility
18 Years and older · Female only
Enrollment
584 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
72
States / cities
Anchorage, Alaska • Scottsdale, Arizona • Tucson, Arizona + 60 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Active, not recruiting Phase 3 Interventional

Outcome Study Assessing a 75 Milligrams (mg) Dose of Macitentan in Patients With Pulmonary Arterial Hypertension

NCT04273945
View directory record Official record
Conditions
Pulmonary Arterial Hypertension
Interventions
Macitentan 10 mg, Macitentan 37.5 mg, Macitentan 75 mg, Placebo
Drug
Lead sponsor
Actelion
Industry
Eligibility
18 Years and older
Enrollment
935 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2029
U.S. locations
43
States / cities
Phoenix, Arizona • Scottsdale, Arizona • La Jolla, California + 35 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Not applicable Interventional

At-Home Genital Nerve Stimulation for SCI Bowel

NCT06836739
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Genital nerve stimulation
Device
Lead sponsor
MetroHealth Medical Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Phase 2 Interventional

Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas

NCT02523014
View directory record Official record
Conditions
Intracranial Meningioma, Recurrent Meningioma, NF2 Gene Mutation
Interventions
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, Abemaciclib
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
791
States / cities
Birmingham, Alabama • Anchorage, Alaska • Fairbanks, Alaska + 512 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Active, not recruiting Phase 2 Interventional

A Study of JNJ-79635322 in Participants With Relapsed or Refractory Multiple Myeloma

NCT07266441
View directory record Official record
Conditions
Multiple Myeloma
Interventions
JNJ-79635322
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
168 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
30
States / cities
Birmingham, Alabama • Gilbert, Arizona • Duarte, California + 24 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Phase 1 Interventional

A Study to Investigate the Safety and Efficacy of KQB368 as Monotherapy in Participants With Advanced Solid Malignancies

NCT07542704
View directory record Official record
Conditions
Advanced Solid Tumors, Colorectal Cancer (CRC), Non-Small Cell Lung Cancer, Uterine Cancer, KRAS G12C Mutations, KRAS G12S Mutations
Interventions
KQB368
Drug
Lead sponsor
Kumquat Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
14
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 11 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Active, not recruiting Phase 1 Interventional

ARX517/JNJ-95298177 as Monotherapy or Combination Therapy in Subjects With Metastatic Prostate Cancer

NCT04662580
View directory record Official record
Conditions
Metastatic Prostate Cancer
Interventions
ARX517, Apalutamide, Abiraterone acetate, Prednisone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 9 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Active, not recruiting Phase 3 Interventional

A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

NCT05083169
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Pomalidomide, Dexamethasone, Bortezomib, Teclistamab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
587 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
18
States / cities
Birmingham, Alabama • Duarte, California • Stanford, California + 14 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Phase 3 Interventional

Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer

NCT06661720
View directory record Official record
Conditions
Clear Cell Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Stage II Renal Pelvis Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8
Interventions
Pembrolizumab, Tivozanib, Biospecimen Collection, MRI, Computed Tomography, Biopsy, Questionnaire Administration
Biological · Drug · Procedure + 1 more
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
1,040 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2037
U.S. locations
429
States / cities
Phoenix, Arizona • Tucson, Arizona • Jonesboro, Arkansas + 340 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST
Recruiting Not applicable Interventional

Living Well With Brain Cancer: A Group-Based Intervention to Promote Whole-Person Well-Being

NCT07628647
View directory record Official record
Conditions
Brain Cancer
Interventions
Group Self-Management Sessions, Educational Materials Only
Behavioral · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Aurora, Colorado • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 3, 2026 · Synced Nov 15, 2026, 2:06 AM EST